Our data clearly indicate that p130Cas up-regulation is implicated in both luminal filling and in tempering Erk1/2 MAPKs levels of activation; two events considered hallmarks of cancer initiation, suggesting that p130Cas over-expression might serve as a bona fide prognostic molecular marker for early breast cancer lesions. The gene discussed is MAPK3; the disease is breast cancer.